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Specific inhibition of the chymotrypsin-like activity of the 
proteasome induces a bipolar morphology in neuroblastoma cells 
Gabriel Fenteany and Stuart L Schreiber 
Background: Lactacystin inhibits cell proliferation and induces a distinctive, 
predominantly bipolar (two-neurite-bearing) morphology in Neuro 2A murine 
neuroblastoma cells. It binds with high specificity to the multicatalytic 205 
proteasome and inhibits at least three of its peptidase activities (chymotrypsin- 
like, trypsin-like and peptidylglutamyl-peptide hydrolyzing), each at a different 
rate, without inhibiting other known proteases. The chymotrypsin-like and trypsin- 
like activities of the proteasome are inhibited most rapidly, and irreversibly. In an 
effort to determine which of the peptidase activities needs to be inhibited for 
neurite outgrowth to occur, we treated Neuro 2A cells with peptide aldehydes 
that selectively inhibit different proteasome activities. i 
Results: Treatment with peptide aldehydes ending in a hydrophobic residue, all 
of which inhibit the chymotrypsin-like activity, results in a bipolar morphology in 
Neuro 2A cells, whereas treatment with a peptide aldehyde inhibitor of the 
trypsin-like activity does not lead to a detectable change in morphology. One of 
the inhibitors that induces neurite outgrowth has been previously shown to inhibit 
the chymotrypsin-like activity of the proteasome without inhibiting the other 
apparently distinct peptidase activities that cleave after neutral residues, the 
so-called ‘branched chain amino acid preferring’ (BrAAP) and ‘small neutral 
amino acid preferring’ (SNAAP) activities, or the peptidylglutamyl-peptide 
hydrolyzing (PGPH) activity., 
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Conclusions: The chymotrypsin-like activity appears to antagonize bipolar-type 
neurite outgrowth in Neuro 2A cells, while the trypsin-like, PGPH, BrAAP and 
SNAAP appear not to do so. Selective inhibition of a single peptidase activity, as 
opposed to general inhibition of the proteasome, appears sufficient to induce a 
specific cellular process. Selective inhibition might be useful in managing 
diseases where only one activity is involved without completely inhibiting the 
proteasome. It is also possible that endogenous regulators of the proteasome 
could affect cellular processes and that certain peptidase activities of the 
proteasome may have roles in specifying a given cetl fate. 
Introduction 
Lactacystin (Fig, 1) inhibirs cell proliferation and induces 
a predominantly bipolar (two-neurite-bearing) type of 
ncurite outgrowth in Neuro ZA murinc neuroblastoma 
cells. The ncurite outgrowth reaches a maximum 14-32 h 
after treatment, with the cells becoming progressively 
more multipolar (multiple-neurite-bearing) and the 
neurites more branched as time goes on [1,2]. The bipolar 
morphology induced by iactacystin is distinct from the 
response to a variety of other common treatments leading 
to differentiation. For example, depriving Neuro 2A cells 
of serum or treating them with agents that raise intra- 
cellular cyclic adcnosine monophosphate (CAMP) levels 
and thus activate protein kinasc A both tend to induce a 
predominantly multipolar morphology [Z-41, whereas 
treatment with retinoic acid, natural gangliosides or syn- 
thetic sialyl compounds tends to induce a more unipolar 
(single-ncurite-bearing) morphology i3,4]. Induction of 
bipolar morphology in response to lactacystin is inhibited 
by phosphatase inhibitors, while branched neurite net- 
work formation around rhrce days following lactacystin 
treatment is not inhibited by phosphatase inhibitors [5]. 
Lactacystin inhibits cell cycle progression in both the Gl 
and G2 phases of the cell cycle [2,6]. 
IJsing radioactively labeled derivatives of lactacystin, the 
target of Lactacystin was purified from bovine brain 
extracts and identified as the 20s proteasome [7]. The 
proreasome is a .bigh molecular weight, multicatalytic 
protease complex that is responsible for ubiquitin-dcpen- 
dent protein degradation within the cel1 (for reviews, see 
[S-11]). The proteasome is capable of both complete 
proteolysis of protein substrates and limited proteolytic 
processing teading to activation of protein function [IZ]. 
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Figure 1 
Lactacystin clasto-Lactacystin 
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Structures of lactacystin and a related 
p-lactone, c/asfo-lactacystin p-lactone, and of 
the peptide aldehydes used in this study. 
Z-LLFal = N-benzyloxycarbonyl-L-leucyl-L- 
leucyl-kphenylanipal; Ac-LLnlal = Nacetyl-k 
leucyl-L-leucyl-L-norleucinal; AceLLMal = 
iV-acetyl-L-ieucyl-L-leucyt-kmethional; leupeptin 
= Nsacetyl-t-leucykL-leucyl-L-argininal. 
The proteasame consists of a multi-subunit catalytic core 
with a sedimentation coefficient of 205 (the 20s protca- 
some) that can degrade peptide and certain protein sub- 
strates independent of the presence of ATP and ubiquitin 
and ‘capping’ subunits that, together with the proteolyti- 
tally active core, form the so-called 2% proteasome which 
is ATP- and ubiquitin-dependent. 
Activities of the proteasotne 
The 20s proteasome is thought co have at least five 
distinct catalytic activities. The most firmly established 
and best characterized of these activities are named the 
chymotrypsin-like, trypsin-like and peptidyIgIutamyl- 
peptide hydrolyzing (PGPH) activities. These cleave on 
the carboxyl side of hydrophobic, basic and acidic 
residues, respectively. Based on inhibitor, activator, 
kinetic and genetic studies, these activities appear to arise 
from separate active sites. Inhibitor studies also provide 
evidence for the existence of two additional peptidase 
activities that cleave after amino acid residues wish 
neutral side chains, which are apparently distinct from the 
chymotrypsin-like activity. One of these cleaves prefer- 
entially after amino acid residues with branched side 
chains (the BrAAP activity), the other between residuts 
with the small neutral sidechains .&zine and alaninc 
(the SNAAP activity) [I3]. There is&idencr to suggest 
that the BrAAP activity is a major contributor to protein 
degradation by the proteasome [13]. 
Lactacyscin binds to the 205 catalytic core of the protca- 
some and- inhibits three of its major peptidase activities, 
the chymotrypsin-like, trypsin-like and PGPH activities, 
fn O&I [7]. Lactacystin also binds to the proteasome 
& viva (data not shown) and inhibits ubiquitin-mediated 
protein degradation, which occurs via the proteasome, 
in w&o and in viva ([ 14,151, and J Hagler, 0 Rando, 
GF, SLS & T Maniatis, unpublished data). There is an 
excellent correlation between the ability of a series of 
analogs of lactacystin to compete with radiolabeled 
lactacystin for binding to the proteasome, inhibiting its 
funcdon and their ability to induce neurice outgrowth in 
Nemo 2A cells [2,7]. Furthermore, lactacystin appears to 
be highly specific for the proteasomc, since no other 
procease tested, including trypsin, chymotrypsin, papain, 
calpain and cachcpsin B [7], thrombin and plasminogen 
activator [l], has been inhibited by lactacystin. it also 
does not inhibit lysosomal protein degradation 1151. 
Lactacystin is unique in terms of its proteasome 
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specificity and, as a result, has become a widely used 
probe of proteasome function. 
T’he rates of inhibition of the chymotrypsin-like, trypsin- 
like and PGPH activities of the 205 proteasome by lacr- 
acystin arc significantly different, and only the two most 
rapidly inhibited activities, chymotrypsin-like and trypsin- 
like, are irreversibly inhibited [7]. The chymotrypsin-like 
activity is inhibited -20 times faster than the trypsin-like 
activity (and -50 times faster than the PGPH activity). A 
@-&tone related to lactacystin, &J&J-lactacystin P-lactone, 
formally the product of elimination of N-acetylcysteine 
from lactacystin, is 15-20 times more potent as an inhibitor 
of all three peptidsse activities than lactacysdn, yet is just as 
specific for the proteasome as is lactacystin [7]. The effects 
of lactacystin appear to be mediated through formation of 
the P-lactone as an active intermediate [lb]. 
In 205 proceasome purified from bovine brain, the time- 
frame of inhibition of the two irreversibly inhibited acriv- 
ities is correlated with binding to one proccasome subunit, 
subunit X (also known as MB]. or E), with which lactacystin 
forms a stable covalent complex in a 21 1actacystin:protein 
stoichiometry [7]. Lactacystin modifies the putatively cat- 
alytic amino-terminal threonine of the mature, proteo- 
lyrically processed subunit X, as we11 as an internal residue 
171. Lactacystin also binds to a second proteasome subunit 
containing chreonine at the amino terminus, now known as 
subunit % (or MC14), in bovine brain proteasome prep- 
arations: however, binding to this second subunit occurs too 
slowly to account for inhibition of the chymotrypsin-like 
and trypsin-like activities, and there is no evidence that the 
amino-terminal threonine of this secondary lactacyscin- 
binding protein is modified by lectacystin [7]. 
Studies in other systems provide further evidence that 
proteasome subunit X and its homologs may have a cat- 
alytic role. Subunits X and Z are P-type proceasome 
subunits, so termed because they are related to the 
P-subunit of the 205 proteasome from the archaeon 
T&mopEu~rna Lscidop/siluna. The T. ucidopAi~tim protea- 
some’s autocatalytically processed P-subunit has an 
amino-terminal threonine that is critical for activity [17]. 
The X-ray crystal structure of the T. ac&p&lum protea- 
some with bound peptide aldehyde inhibitor also suggests 
that this residue is part of the active site and chat the 
sidechain hydroxyl may be involved in nuclcophilic attack 
on the amide carbonyl carbon of peptide substrates [18]. 
The yeast homolog of subunit X, PreZ, has an amino- 
terminal threonine as well, and this subunit is required for 
chymotrypsin-like activity and the degradation of ubiqui- 
tinated proteins 1191. The proteasome is therefore a 
member of the recently recognized amino-terminal 
nucleophile hydrolase family of proteins. These proteins 
all appear to be processed from precursor proteins to 
generate amino-terminal nucleophilic residues (threoninc, 
serine or cysteine) and to have a similar fold in the active- 
site region, providing the capacity for nucleophilic attack 
and the possibihty for autocatalytic processing [ZO-221 . 
It is now well established that the proteasome is involved in 
the generation of antigens for class I major histocompat- 
ibility (MAC) presentation, and that two proteasome 
suhunits encoded in the class II MHC region, LMP7 (a 
closely related homolog of subunit X) and LMPZ (related to 
another subunit termed Y or S), may be important in the 
immune response (for reviews, see [9,10,23]). Mice with a 
targeted deletion of LMP7 exhibit reduced levels of MI-IC 
class I expression at the cell surface and inefficient antigen 
presentation 1241. LMPZ appears to be needed for pre- 
sentation of certain class I MI-IC antigens to cytotoxic T 
lymphocytes [ZS]. Treatment of mammalian cells with y- 
interferon alters the peptidase activities of the pruteasome 
[Z&29] and results in down-regulation of subunits X and Y 
and up-regulation of LMP7 and LMPZ [3O-321. A similar 
reciprocal relationship also exists between subunit 2 and 
the r&red y-interferon-inducible subunit MECLl (also 
known as LMPlO) [33,34]. ‘These results imply chat LMPZ 
and LMP7 (and possibly MECL1) are partly responsible for 
optimizing the proteasome for generation of antigenic 
peptides for class I MHC presentation by inducibly taking 
over the roles of their normally expressed cognates, 
Lactacystin-binding subunits 
It has recently been shown that, in addition to subunits X 
and 2, four other P-type subunits, Y, LMPZ, LMP7 and 
MECLl, all of which have a threonine at their amino- 
terminus, are capable of binding lactacystin in lymphobiast 
cells 1151, although there is as yet no evidence to suggest 
that the amino-terminal threonine residues of these other 
subunits are covalently modified. Therefore, six putatively 
catalytic proteasome subunits, falling into three groups of 
related and reciprocally regulated subunits, appear to be 
able to bind lactacystin, and none of the other subunits of 
the proteasome bind lactacystin [7,15]. 
Lacracystin is uniquely specific for the pruteasome versus 
other proteases; however, it inhibits multiple proteasome 
peptidase activities [7]. In an attempt ro determine which 
of the peptidase activities of the proteasome needs to be 
inhibited to induce a bipolar morphology in Neuro 2A cells, 
we created cells with cell-permeable peptide aldehydes that 
inhihit subsets of the proteasome’s peptidase activities. We 
found that treatment with inhibitors ending in hydrophobic 
residues resulted in bipolar-type neurite outgrowth that 
was very similar to chat induced by lactacystin, while 
treatment with an inhibitor of the trypsin-like activity did 
not result in any deccctable difference in morphology from 
untreated control cells. One of the inhibitors tested and 
found to induce neurite outgrowth, N-benzyloxycarbonyl- 
leucine-leucine-phenylalnninal (Z-LLFal), has been previ- 
ously shown to inhibit the chymotrypsin-like activity of the --_ 
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Figure 2 
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Percentage of Neuro 2A cells exhibiting unipolar (a), bipolar(b) ar 
multipolar (c) morphology as a function of time after the following 
treatments: 1 % DMSO (black, a); 10 PM lactacystk (purple, 0); 
1 WM Z-LLFat (red, 0); 5 p.M Ac-LLnLal (green, a); 50 ~J.M Ac-LLMal 
(light blue, W); 1 mM leupeptin (pink, l ). Each value is the mean of 
triplicate samples, and the bars correspond to + the standard deviation. 
proteasome without affecting the two other apparently 
distinct activities that cleave after neutral residues, RrAAP 
and SNAAP activities [13], or the PGPH activity [SSJ. 
‘Thus, inhibition of the chymotrypsin-like activity appears 
to be responsible for the induction of a bipolar morphology 
in Neuro 2A cells. 
Results and discussion 
Specificity of peptide aldehyde inhibitors 
Z-LLFal has previously been shown to inhibit the 
chymotrypsin-like activity without detectably inhibiting 
the two other ncucral amino acid preferring activities 
(BrAAP and SNAAP) [13] or the PGPH activity [35]. 
1V-Acetyl-rJ-leucyl-L-leucyl-L-norleucinal (Ac-LLnLal) and 
N-acetyl-I,-lcucyl-I.,-lrucyl-L-methional (Ac-LLMal) also 
end in hydrophobic residues and sctectively inhibit the 
chytnotrypsin-like activity of the protcasome in in vitro 
studies [35,36]. However, unlike Z-LLFal, these two com- 
pounds also appear to inhibit, at least partially, the BrAAP 
and SNAAP activities 1131. Leupeptin (N-acetyl-L-leucyl-t,- 
Ieucyl-I,-argininal) inhibits the trypsin-like activity of the 
proteasome with a Ki of about 1 FM in vitm 1371 without 
detectably inhibiting any other proteasome peptidase 
activity [13,37,38]. Unfortunately, currently available 
inhibitors of the BrAAP, SNAAP and PGPH activities are 
not very selective. 
Z-LLFal inhibits the proteasome’s chymotrypsin-like 
activity with a Ki of 0.46 2 0.14 FM (mean IdUe 2 
standard error) z% ~,itru 1351 , which is -lOO-fold lower than 
its Ki for the crypsin-like activity, but does not detectably 
inhibit the PGPH, BrAAP or SNAAP activities [13,35]. Ac- 
LLnLal inhibits the chymotrypsin-like activity of the 
bovine pituitary 20s prouxsome in o&o with a ,K. of 5.7 ? 
0.16 PM [35], while AC-LLMal inhibits this activity with a 
Ki of 33.4 + 6.8 FM 1351. Rock d aI. reported lower Ki 
values of 0.14 FM for Ac-LLnLal and 1.0 FM for Ac- 
LLMal for the rabbit muscte ZOS proteasome, and Ki 
values of 0.67 PM and 28 FM, respectively, for rabbit 
muscle 26s proteasome [36]. Roth Ac-LLnLal and AC- 
LLMal also inhibitlthc trypsin-like and PGPH activities of 
the proteasome, though with higher Ki values than for the 
chymotrypsin-like activity [35,36], and at least partially 
inhibit the HrAAP and SNAAP activities of the proteasome 
1131. It therefore appears that, of the pepcide aldehydes 
ending in hydrophobic residues, Z-LLFal is by far the 
most specific inhibitor of the chymotrypsin-like activity. 
PepCde aldehydes ending in either hydrophobic or basic 
residues appear cell-permeable, although a higher con- 
centration of a peptide aldehyde ending in a basic residue 
seems necessary to inhibit: protein degradation. Studies 
using radioactively labeled leupeptin demonstrate that 
teupeptin can penetrate into the cytosol of cultured cells 
and inhibit the calcium-activated neutral prorease calpain 
[39]. Leupeptin has been shown to inhibit N-85 % of 
lysosomal and -15 % of non-lysosomal protein degradation 
in cultured cells at a concentration of 0.3 mM [40]. The 
pepcide aldchydes Ac-LLnLal and Ac-CLMal have also 
been shown to inhibit protein degradation in cultured 
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cells [36]. IC is reasonable to presume that Z-LLFal, which 
is hydrophobic and highly active in inducing bipolar mor- 
phology, can also penetrate the cell. 
Effects of peptide aldehyde inhibitors 
‘Treatment of Neuro 2A neuroblastoma cells with any 
one of the peptide aldehydes that end with hydrophobic 
residues (Z-LLFal, Ac-LLnLaI and AC-LLMal) results in 
reduced cell proliferation and the induction of a bipolar 
morphology (Figs 2b,3), in which two neurites extend from 
opposite sides of the cell body. The cells become pro- 
gressively more multipolar with prolonged exposure to 
these peptide aldehydes as with lactacystin (Fig. Zc), while 
the proportion of unipolar cells in each case is low at every 
.time point (Fig. Za). The morphology induced by treat- 
ment with Z-LLFal (or by Ac-LLnLal or Ac-1,LMal) is 
indistinguishable from that induced by lactacystin (Fig. 3). 
In contrast, treatment with leupeptin, which inhibits the 
trypsin-like activity of the proteasome without inhibiting 
Figure 3 
any of its other pepcidase activities [13,37,38], does not 
lead to any detectable difference in cell morphology from 
untreated control cells even at the elevared concentration 
of 1 mM (Figs 2,3). Although it is not clear at this point 
how important the nypsin-like activity of the protcasomc 
is in determining overall rates of protein breakdown, our 
results show that inhihition of rhis activity - whatever its 
normal physiological function - does not result in neurice 
outgrowth. Furthermore, since leupeptin inhibits the 
cytosolic proteasc calpain [39] and many extracellular and 
lysosomal proteases [41,42], it is unlikely that inhibition of 
such proteases could mediate the induction of bipolar-type 
neurice outgrowth in Ncuro 2A cells. 
Inhibition of the chymotrypsin-like activity of the pro- 
teasome, without inhibition of the ocher two neutral amino 
acid preferring activities, appears to be sufficient to induce 
neurite outgrowth in Neuro 2A cells, since Z-LLFal 
inhibits only the chymotrypsin-like activity of the three 
neutral amino acid preferring activities [13]. Z-LLFal does 
Photomicrographs of Neuro 2A cells 24 h after treatment with: (a) 1 % 
DMSO; (b) 10 FM lactacystin; (c) 1 PM Z-LLFal; (d) 1 mM leupeptin. 
The length of the bars corresponds to 100 pm. 
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nor inhibit The PGPH activity and significancly inhibits the 
trypsin-like activity only at elevated concentrations [35], 
while treatment with leupepcin, which only inhibits the 
crypsin-like activity of the proteasome’s activities, does not 
lead to neurite outgrowth (Figs 2,3). Taken together with 
previous results using the proteasome-specific inhibitor 
lactacystin [.2,7], these results imply char. inhibition of the 
chymocrypsin-like activity is responsible for the neurite 
outgrowth that results from proteasome inhibition. Since ir 
appears not to be necessary to inhibit the other peptidase 
activities of the proteasome for neurice outgrowth to occur, 
only the chymotrypsin-like activity appears co antagonize 
neurite outgrowth. 
Z-LLFal is the most potent inducer of neurite outgrowth 
on the basis of the concentration required for activity, 
followed by Ac-LL,nLal and then Ac-LLMal (Fig. 2 
and data not shown). This order of effectiveness also 
corresponds to the order of potency of these peptide 
aldehydes for inhibition of the proteasome’s chymo- 
trypsin-like activity [3.5,36]. Since the more potent 
inducers of ncurite outgrowth are also the more potent 
inhibitors of the chymotrypsin-like activity, the neurito- 
genie potency of a peptide aldehyde may be determined 
by its effectiveness as an inhibitor of the proceasomc’s 
chymotrypsin-like acriviry. 
Relevance of the cellular response 
Bipolar-type neurite outgrowth in response to lactacystin 
or the peptide aldehydes ending in hydrophobic residues 
does not appear to be a non-specific cellular response 
to stress. Treatment of Neuro 2A cells with cytotoxic 
concentrations of various compounds leads to rounding 
up of cells and ultimately to detachment from the sub- 
stratum without any induction of bipolar inorphology at 
any point (data not shown). Although elevated con- 
centrations of lactacystin and the neuritogenically active 
peptide aldehydes are cytotoxic, lower concentrations 
sufficient to induce bipolar morphology do not result in 
rounding up and death of cells (Fig. 2 and data not 
shown). In contrast, sub-cytotoxic concentrations of a 
variety of other growth-inhibitory compounds do not 
result in bipolar-type neurite outgrowth (data not 
shown). Lactacystin and the neuritogenically active 
peptide aldehydcs examined are alone among inhibitors 
of cell pruliferation and inducers of differentiation in 
that treatment results in a mainly bipolar type of neurite 
outgrowth. While inhibition of the chymotrypsin-like 
activity of the proteasome may represent a specific and 
limited kind of cellular stress, the response of the ceils 
is unique in terms of the predominant morphology 
induced. It is therefore reasonable to assume that the 
chymotrypsin-like activity of the proreasome is required 
either to destroy a protein that directly ‘or indirectly 
promotes neurite outgrowth, or to activate a protein that 
antagonizes neurire outgrowth. 
Two of the peptide aldehydes that induce neurice out- 
growth, Ac-LLnLal and Ac-LLMal, have also been shown 
to inhibit cnrhepsin B and calpain [36]. Lactacystin, 
however, inhibits neither of these proteases [7]. It is, of 
course, possible that bipolar-type neurice outgrowth in 
response co the peptide aldchydes occurs by a different 
mechanism rhan with lactacystin. But as the observations 
show that the morphology of the cells rreaced with these 
compounds is comparable to that of cells treated with 
lactacystin, and as neuritogenic potency of these com- 
pounds correlates with their ability to inhibit the pro- 
teasome’s chymotrypsin-like activity, it seems more likely 
that the mechanism involved is similar. 
Certain rripeptide aldehydes, including N-benzyloxy- 
carbonyl-Leu-Lcu-leucinal (Z-LLLal), induce neurite 
outgrowth in PC12 rat pheochromocytoma cells, and 
purification of the N-benzyloxycarhonyl-Leu-Leu-Leu-7- 
amido-4-methylcoumarin-degrading activity reveals that 
the proteasome is the main target [43]. Lactacystio, 
however, does not have any detectable neuritogenic effect 
on PC12 cells but does exhibit a dose-dependent toxic 
effect [Z]. It is thtircfore possible that the actual targer that 
mediates neurite outgrowth in PC12 cells in response to 
Z-LLLal is a proteasc other than the protcasome. It is also 
possible chat lactacystin, though uniquely specific for the 
proteasome versus other proteases, may inhibit a broader 
range of the proteasome’s peptidase activities than does 
Z-LLLal. For example, if the proteasome normally 
activates a protein that antagonizes neurite outgrowth, a 
second proteasome activity might be required in PC12 
cells CO ensure its continued activity. If both activities are 
inhibited by lactacystin, but only the first is inhibited by 
Z-LLLal, then Z-LLLal, but not lactacystin, would 
induce neurite outgrowth in these cells. 
Inhibition of the proteasome’s chymotrypsin-like activity 
may promote bipolar neurite outgrowth in Neuro ZA cells 
by either preventing the degradation of a protein that 
promotes bipolar neurite outgrowth OF preventing the 
proceolytic activation of a protein that antagonizes bipolar 
neurite outgrowth. The results presented here suggest 
that the chymotrypsin-like activity is involved, direcdy or 
indirectly, in the degradation or proteolytic activation of 
the putative substrate(s) of the proteasornc that either 
positively or negatively regulates the induction of a 
bipolar morphology, There are two simple explanations 
for the importance of the chymotrypsin-like activity in the 
regularion of neurite outgrowth, although more compli- 
cated models can also be envisioned. The chymorrypsin- 
like activity may be solely responsible for the relevant 
cleavage of the substrate, most plausibly leading to an 
activation of the substrate’s function. Alternatively, the 
chymotrypsin-like protease activity may be required for 
the first step in the processive degradation of the substrate 
involved in neurite outgrowth. In the first case, it is the 
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inhibition of a specific cleavage(s) of the substrate by the 
chymotrypsin-like that leads to neurice outgrowth, In the 
second case, inhibition of the chymotrypsin-like activity 
prevents or significantly retards proreolysis of the sub- 
strate by not only the chymotrypsin-like activity itself but 
also the other activities. This could prevent either an 
inactivating proteolysis of the substrate by any site or an 
activating cleavage by another sire. In this case, it is 
necessary to suppose that inhibition of the trypsin-like 
activity does not prevent proteolysis of the substrate by 
the chymotrypsin-like or other activities. 
Ic is not clear whether neurite outgrowth in response to 
inhibition of the chymotrypsin-like activity of the protea- 
some reflects a normal, endogenous mechanism for the 
induction of differentiation or not. Endogenous modulators 
of the proteasome’s activities have been discovered (for 
review, see [8]). Some affect multiple peptidase activities, 
while others appear more specific. It is possible that such 
regulators are expressed in a cell-specific manner and help 
co determine the fate of a cell during development. 
Significance 
The proteasome’s chymotrypsin-like activity, but not 
its trypsin-like, PGPH, BrAAP or SNAAP activities, 
appears to antagonize neurite outgrowth in Neuro 2A 
neuroblastoma cells. Other cellular processes may also 
be promoted or inhibited by selective inhibition of a given 
peptidase activity of the proteasome. Such selective 
inhibition may be useful not only in research but also in 
managing disease where one proteasume a&vi@ is pri- 
marily involved. This might reduce the toxicity expected 
to result from the general inhibition of the proteasome. 
The results reported herein demonstrate that modulation 
of a specific proteolytic activity can be responsible for a 
cellular phenotype. Unique peptidase activities of the 
proteasome may have roles in determining the physiology 
and fate of a ceil. 
Materials and methods 
Neuro 2A cells were cultured in minirnal essential medium containing 
10 % fetal bovine serum, L-glutamine and non-essential amino acids 
(complete medium). The cells were plated to a density of -1 x t04 
cells per well in 1 Z- or 24-well polystyrene dishes in a volume of 1 ml of 
complete medium and grown for 24 h prior to treatment. Ail the peptide 
aldehydes were purchased from BACHEM Bioscience Inc. (King of 
Prussia, PA), except for Z-LLFal, which was prepared by the SynPep 
Corporation (Dublin, CA). Short-term stock solutions of peptide 
aldehydes were stored as high concentration solutions in dimethyi 
sulfoxide at -20” C, thawed prior to use and added to cell culture 
dishes. Ceil density and the percentage of cells exhibiting unipolar, 
bipolar or multipolar morphology were determined using phase- 
contrast microscopy at various time points foliowing treatment. 
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